A Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension Group 2 - Re-PHIRE

Study identifier:D8330C00003

ClinicalTrials.gov identifier:NCT05737940

EudraCT identifier:N/A

CTIS identifier:2022-502382-25-00

Recruiting

Official Title

A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)

Medical condition

Pulmonary Hypertension (World Health Organization Group 2)

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD3427, Placebo

Sex

All

Estimated Enrollment

220

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 24 Apr 2023
Estimated Primary Completion Date: 23 Apr 2025
Estimated Study Completion Date: 26 Aug 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria